document incorporate reference specify portion registrant definitive proxy statement file commission pursuant regulation connection annual meeting incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrant gilead sciences inc annual report table content item business item property item legal proceeding item submission matter vote security holder ii item market registrant common stock relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management item certain relationship relate transaction item principal accountant fee service iv item exhibit financial statement schedule report form k signature right trademark copyright trade name business include follow gilead gilead sciences hepsera leaf shield design leaf shield design bw liver design tablet design bw tablet design color viread vistide daunoxome ambisome emtriva tamiflu register trademark belong hoffmannla roche report include trademark service mark trade name company item business forwardlooke statement risk factor report include forwardlooke statement particular statement expectation belief plan objective assumption future event performance contain incorporate reference report base forwardlooke statement current expectation future event believe expectation reasonable forwardlooke statement inherently subject risk uncertainty control actual result differ materially suggest forwardlooke statement reason include discuss report head risk factor affect gilead give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof undertake specifically decline obligation update statement publicly announce result revision statement reflect future event development report indicate refer gilead subsidiary overview gilead sciences inc biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease worldwide product currently market market country worldwide research clinical program focus antiinfective include antiviral antifungal endeavor grow exist portfolio product proprietary clinical development program internal discovery program active product acquisition inlicense strategy worldwide headquarters foster city california european headquarters paris france incorporate delaware june january complete acquisition net asset triangle pharmaceuticals inc triangle expand antiviral pipeline aggregate purchase price million include cash pay outstanding stock fair value stock option assume estimate direct transaction cost employee relate cost approximately million purchase price record inprocess research development expense triangle develop drug candidate antiviral area particular focus potential therapy hiv include aids hepatitis b virus triangle portfolio consist drug candidate clinical trial include emtrivatm emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july food drug administration fda approve marketing emtriva treatment hiv october european commission grant marketing authorisation emtriva member states european union subsequently return right amdoxovir clevudine licensor commercial interest compound product viread approve sale sell commercial team use combination antiretroviral agent treatment hiv infection viread sell internationally international commercial team include european union australia emtriva approve sale sell commercial team use combination antiretroviral agent treatment hiv infection adult emtriva sell european union international commercial team currently develop fixeddose combination viread emtriva ambisome approve sale sell country treatment lifethreatening fungal infection country prevention infection market ambisome major country europe copromote ambisome fujisawa healthcare inc fujisawa hepsera approve sale sell commercial team treatment chronic hepatitis b hepsera receive marketing approval european union march launch country european union additional launches country european union part world expect occur tamiflu approve sale sell corporate partner hoffmannla roche roche country include european union prevention treatment influenza japan approve treatment influenza vistide approve sale sell commercial team gilead exus partner pfizer inc pfizer pharmacia corporation country treatment cytomegalovirus cmv retinitis patient aid daunoxome approve sale sell country treatment aidsrelate kaposis sarcoma sell commercial team independent distributor abroad december decide discontinue selling product earn revenue million sale royalty product sale viread generate aggregate product sale royalty revenue million total revenue sale ambisome generate aggregate product sale royalty revenue million total revenue earn revenue sale royalty product million million million outside earn revenue sale royalty product million million million viread tenofovir disoproxil fumarate viread oral formulation nucleotide analogue reverse transcriptase inhibitor tenofovir df dose day combination therapy treat hiv infection adult drug work block reverse transcriptase enzyme involve replication hiv sell viread commercial team major european country european commercial team commercial operation fda approve viread market october european agency evaluation medicinal product emea grant similar approval european union february emea expand indication viread include use antiretroviralnave hiv infect patient august fda similarly expand indication viread viread approve use combination antiretroviral agent treatment hiv infection indication base analyse plasma hiv rna level cd cell count control dose range study viread week duration study placebocontrolle study viread week duration study study conduct treatmentexperienced adult evidence hiv viral replication despite ongoing antiretroviral therapy expand indication base week result ongoing threeyear randomize doubleblind clinical trial study design compare efficacy safety combination treatment regimen viread lamivudine tc efavirenz combination treatment regimen stavudine dt lamivudine efavirenz antiretroviralnave patient hiv infection february report week datum study datum study demonstrate treatmentnave patient receive viread experience substantially lipodystrophy low elevation fast cholesterol triglyceride level improved level limb fat weight gain achieve similar reduction hiv viral load increase cd cell count compare receive stavudine common adverse event report include viral infection diarrhea headache occur similar frequency study arm discontinuation rate approximately percent patient viread arm percent patient stavudine arm week datum supplement week result study submit fda support use viread major challenge treat hivinfecte patient drug resistance exist therapy treat hiv infection aid rely similarlydesigne drug process patient develop resistance drug develop resistance drug class believe viread approve regulatory authority offer advantage approve hiv treatment available datum show patient develop resistance viread viread effective treat patient develop resistance therapy certain resistance datum obtain completion phase clinical trial similar resistance characteristic week datum study datum obtain limited phase clinical trial major concern hiv treatment convenience dose combination therapie positive impact require hivinfected patient numerous drug drug require multiple dose day time dietary restriction result inconvenience patient contribute patient miss dose adhere therapy viread approve administer oncedaily oral pill schedule appeal hivinfecte patient physicians hiv competitive landscape crowd complicated treatment trend continue evolve twentytwo brand antihiv drug currently sell advance stage clinical development competition exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega obligate pay percentage net revenue sale viread european union country product approve patent protection iocbrega academic consulting relationshipsiocbrega emtriva emtricitabine emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult sell emtriva commercial team major european country european commercial team commercial operation fda approve emtriva market treatment hiv july european commission grant marketing authorisation emtriva member states european union october emtriva antiviral agent hiv strain obtain geographically diverse set hivinfecte patient laboratory study show emtriva share crossresistance pattern lamivudine common resistance mutation agent reverse resistance hiv azt case phase clinical study emtriva complete collaboration agence nationale de recherche sur le sida anrs france study study ftc compare emtriva mg onceaday stavudine mg twiceaday combination didanosine mg onceaday efavirenz mg onceaday patient previous antiretroviral therapy july independent data safety monitoring board dsmb establish provide oversight study recommend emtriva offer patient enrol study interim result evaluate studys dsmb show emtriva arm statistically superior stavudine arm primary secondary endpoint safety efficacy eightyseven percent patient onceaday emtriva arm persistent virologic response month compare twicedaily stavudine arm patient emtriva arm significant improvement immunologic function view compelling difference favor emtriva arm dsmb recommend study amend patient give option switch openlabel emtriva continue blind therapy randomize patient complete week october final analysis study confirm superior efficacy safety emtriva compare stavudine combination didanosine efavirenz exclusive worldwide license patent right relate technology emtriva emory university academic consulting relationshipsemory university university georgia research foundation ambisome amphotericin b liposome injection ambisome proprietary liposomal formulation amphotericin b amphotericin b powerful antifungal agent know ability treat invasive fungal infection cause fungal specie infection generally life threaten particularly patient depressed immune system aggressive chemotherapy regimen stem cell organ transplant hiv infection amphotericin b treatment effect includingkidney toxicity study deliver amphotericin b proprietary liposomal formulation ambisome reduce rate severity kidney toxicity injectionrelate reaction allow patient receive high dose amphotericin b ambisome approve sale country include european union rest europe australia canada country middle east latin america asia countries ambisome approve include authorize promote ambisome empirical treatment fungal infection ie treatment patient strong suspicion definite confirmation exist potentially lifethreatene invasive fungal infection remain country ambisome approve sale approve use firstline treatment invasive fungal infection secondline treatment conventional amphotericin b therapy fail conventional amphotericin b tolerate finally ambisome approve number country indication example cryptococcal meningitis aids patient prophylaxis liver transplant patient visceral leishmaniasis copromote ambisome fujisawa commercial team agreement fujisawa entitle percentage revenue generate sale provide fujisawa purchase ambisome manufacturing cost collaborative relationshipsfujisawa major european country australia sell ambisome international commercial team certain country sell ambisome independent distributor revenue ambisome europe expect case foreseeable future license commercial right ambisome japan sumitomo pharmaceuticals co ltd sumitomo exchange royalty generate activity ambisome approve sale japan ambisome face strong competition current competitor expect competitor treatment late stage clinical trial competition competition current expect competitor likely erode revenue receive sale ambisome hepsera adefovir dipivoxil hepsera oral formulation nucleotide analogue hbv dna polymerase inhibitor adefovir dipivoxil dosed day treat chronic hepatitis b hepatitis b cause highly contagious hepatitis b virus hbv cause acute liver failure patient develop chronic hepatitis b infection year lead complication cirrhosis liver cancer liver failure approximately patient result death accord recent estimate world health organization center disease control million people worldwide million people chronic hepatitis b million death attributable chronic hepatitis b worldwide year lead cause death worldwide hepsera disable hbv interfere activity enzyme know hbv polymerase necessary virus replicate application european union marketing authorization include datum separate phase clinical trial design evaluate safety efficacy hepsera mg dosage treat patient hepatitis b virus phase trial design randomize doubleblind placebocontrolle study clinical site canada europe australia southeast asia study evaluate hepsera treat patient test positive hbv e antigen common type hepatitis b trial study evaluate hepsera treat patient type hepatitis b know precore mutant hepatitis b common southeast asian mediterranean country week adefovirassociate resistance mutation identify hepatitis b patient treat clinical trial suggest development resistance hepsera hepatitis b patient delay infrequent consequently believe hepseras resistance profile important drug treat chronic hepatitis b certain resistance datum obtain continue phase clinical trial hepsera continue resistance characteristic hepsera approve sale treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team sell hepsera march apply approval emea hepsera treatment chronic hepatitis b european union approval emea recommend committee proprietary medicinal product cpmp november receive march plan sell hepsera major european union country european commercial team vaccine available prevent transmission hbv effective people chronically infect hbv expect vaccine widely available incidence new hepatitis b infection decrease advance prevention hepatitis b individual suffer chronic hepatitis b represent patient pool significant risk morbidity mortality underlie chronic viral infection chronic hepatitis b common china southeast asia commence phase clinical trial china june license rights commercialize hepsera solely treatment hepatitis b china korea japan taiwan rest asia latin america certain territory glaxosmithkline gsk date gsk begin sell hepsera hong kong singapore philippine indonesia pakistan china hepsera grant class designation hepsera ultimately approve sale china gsk year market exclusivity hepsera respect competitor able begin clinical development adefovir dipivoxil follow approval receive chinese government approval phase study give approval forward phase program complete patient enrollment march exist therapy treat patient infect hbv compete hepsera treatment represent significant competition hepsera competition exclusive worldwide license patent right relate technology adefovir dipivoxil iocbrega pay percentage net revenue sale hepsera iocbrega country product patent protection include european union addition pay small variable percentage net revenue sales hepsera md anderson cancer center academic consulting relationshipsmd anderson cancer center tamiflu oseltamivir phosphate tamiflu oral pill treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor act disable common strain flu virus prevent virus spread patient approve treatment influenza tamiflu show reduce duration flu adult average reduce severity flu symptom incidence secondary infectionswhen take approve prevention influenza study show tamiflu effective prevent development flu tamiflu approve country include japan european union treatment influenza child adult tamiflu approve european union prevention influenza adolescent adult develop tamiflu roche roche exclusive right manufacture sell tamiflu subject obligation pay percentage net revenue roche generate tamiflu sale date roche sale tamiflu significantly expectation roche experience problem manufacture distribution tamiflu reduce net sale royalty material effect revenue collaborative relationshipsroche product available treat flu time show effective safe neuraminidase inhibitor competition tamiflu market alternative influenza vaccination believe influenza vaccination remain effective method prevent flu vistide cidofovir injection vistide antiviral medication treatment cmv retinitis patient aid cmv retinitis condition characterize lesion form patient retina affect person weaken immune system common patient aid leave untreated cmv retinitis lead blindness vistide approve sale european union country demand vistide low product revenue immaterial commercial team sell vistide outside pfizer exclusive right sell vistide pfizer pay percentage revenue generate sale vistide collaborative relationshipspfizer active agent vistide cidofovir consider government strategy deal potential bioterrorism attack involve smallpox lifethreatene highly communicable infectious disease laboratory test cidofovir demonstrate activity strain virus cause smallpox current clinical trial diluted smallpox vaccine conduct national institute allergy infectious disease cidofovir consider potential treatment vaccinia infection adverse reaction cause smallpox vaccine additionally national institutes health hold investigational new drug application ind allow emergency use cidofovir smallpox outbreak marketing approval fda know efficacy cidofovir emergency use effect appear use cidofovir smallpox predict country government stockpile vistide treatment smallpox daunoxome daunorubicin citrate liposome injection daunoxome liposomal formulation anticancer agent daunorubicin firstline therapy treat patient suffer certain type hiv associate kaposis sarcoma disease characterize widely disseminate lesion skin mucous membrane lymph node viscera life threaten patient suffer aid daunoxome approve sale country sell daunoxome sell abroad independent distributor demand daunoxome low product revenue immaterial december decision discontinue sell product product clinical trial fixeddose combination viread emtriva currently develop fixeddose combination viread emtriva complete bioequivalence study evaluate systemic exposure patient combination tablet comparison individual product take currently conduct week trial emtriva viread take separate pill emtricitabine hepatitis b emtricitabine show inhibitor hepatitis b virus replication patient chronically infect hbv currently phase clinical development emtricitabine treatment chronic hepatitis b development activity undertake emtricitabine treatment hiv assessment emtricitabine treatment chronic hepatitis b november announce result week clinical trial compare efficacy safety emtricitabine mg day versus placebo patient chronic hepatitis b study ftcb believe second phase clinical trial necessary emtricitabine submit review regulatory agency second phase trial design strategy emtricitabine treatment hepatitis b evolve gs gs novel nucleotide analogue reverse transcriptase inhibitor process body yield tenofovir active chemical yield viread selectively lymphatic cell chemical composition gs allow cross cell membrane easily viread lead great potency viread base datum phase clinical trial gs begin develop phase program treatment hiv infection evaluate patient treatment naive highly resistant thymidine analogue research development seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquisition triangle complete january research scientist foster city san dimas california durham north carolina engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area life threaten infectious disease total research development rd expense million compare million million nucleotide analogues scientist work proprietary nucleotide analogue develop treatment viral infection compound treat viral infection interfere activity certain enzyme necessary virus grow believe small molecule nucleotide analogue offer advantage therapeutic molecule demonstrate ability work bothinfecte uninfected cell enable develop drug treat patient infected virus prevent healthy person infect place second drug develop molecule show treatment activity patient long period time available drug enable develop drug require frequent dose convenient patient hiv protease inhibitor evaluate number small molecule compound know protease inhibitor potential treatment hiv infection protease inhibitor act interfere activity protease enzyme like reverse transcriptase necessary replication hiv conduct number preclinical experiment compound demonstrate potent antiviral activity lead candidate gs know gs currently undergo extensive preclinical evaluation submit investigational new drug application fda gs january antiviral research undertake additional research area treatment viral disease effort focus potential target hiv therapeutic drug significant research effort aim hepatitis c viral infection collaborative relationshipschiron corporation commercial operation international commercial sale operation marketing subsidiary united kingdom germany italy spain france portugal greece australia commercial team promote sell viread emtriva hepsera ambisome europe australia ambisome sell fujisawa sumitomo japan gsk promote sell hepsera asia south america sell vistide commercial partner pfizer sell vistide outside commercial partner roche promote sell tamiflu sell japan tobacco inc japan tobacco promote sell viread emtriva japan approve japanese regulatory authority commercial team promote viread emtriva hepsera direct field contact physician hospital clinic healthcare provider involve treatment patient hiv viread chronic hepatitis b hepsera promote ambisome infectious disease specialist hematologist intensive care unit hospital home health care provider cancer specialist european commercial team support medical sale operation market financial regulatory legal affair manufacture human resource information technology personnel locate primarily european headquarters paris france australian commercial team support worldwide headquarters foster city california country outside agreement thirdparty distributor include distributor certain country market operation promote sell distribute viread emtriva hepsera ambisome international distribution agreement generally provide distributor exclusive right sell viread emtriva ambisome particular country country specify period time january announce program pursuant sell viread cost country africa country designate develop country united nations take step ensure viread product sell program serve patient develop world divert market international distribution support expand commercialization viread hepsera emtriva significantly increase sale force devote additional marketing resource improve coverage healthcare professional treat hivinfecte hbvinfecte patient significantly increase size commercial operation europe manage commercialization viread emtriva hepsera european union april enter licensing agreement gsk gsk receive exclusive right commercialize hepsera asia latin america africa certain territory agreement retain right hepsera canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b country significant include china korea japan taiwan gsk responsibility development commercialization hepsera territory july enter licensing agreement japan tobacco japan tobacco commercialize product gilead hiv portfolio japan agreement include viread emtriva future coformulation product japan tobacco submit application viread expect submit application emtriva coformulation product japanese regulatory authority year viread hepsera emtriva vistide daunoxome returnable original unopened container expiration year expiration date damage receive customer customer return ambisome shelf life expire product damage defective customer receive ambisome approve shelf life month month european country daunoxome shelf life week european country viread shelf life month european union hepsera shelf life month european union emtriva shelf life month european union date return rebate discount material financial result fujisawa establish return policy ambisome north america roche establish return policy tamiflu end flu season significant return tamiflu roche reduce net sale royalty roche base additionally certain governmental agency customer state aids drug assistance program entitle receive discount require provide rebate state medicaid program believe provide adequate provision discount rebates accordance revenue recognition policy collaborative relationship business strategy establish collaboration company assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire company product right product technology complementary business accounting relationship find note consolidated financial statement include report exist collaborative relationship follow archemix corporation october enter agreement archemix corporation archemix agreement grant archemix exclusive sublicense selex technology identify aptamer subject exclusion development area right grant forfeited right tothe selex technology derive license university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation financial term agreement archemix provide lump sum payment total million archemix payment receive warrant purchase archemix stock agreement require agreement ulehi share portion cash payment transfer warrants ulehi academic consulting relationshipsuniversity license equity holdings inc chiron corporation august enter nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutic select hepatitis c virus hcv drug target agreement receive nonexclusive right chiron hcv technology drug screening purpose expect technology assist research discovery effort identify develop potential hcv therapy term agreement pay chiron upfront license fee agree milestone payment royalty payment product develop licensed technology eyetech pharmaceutical march enter agreement eyetech pharmaceuticals inc eyetech relate product name macugen develop treatment agerelate macular degeneration amd diabetic macular edema dme invent compound macugen base nx selex technology license ulehi academic consulting relationshipsuniversity license equity holdings inc license nx eyetech develop macugen license eyetech require pay fee milestone payment percentage revenue generate worldwide sale macugen addition eyetech grant warrant purchase eyetech prefer stock agreement eyetech expire later year commercial sale product develop date patent expire agreement eyetech grant pfizer sublicense relate macugen december december connection sublicense enter license pfizer term contain agreement eyetech december enter agreement eyetech supply macugen eyetech year fujisawa enter agreement grant fujisawa exclusive right promote sell ambisome canada primary responsibility promote sell ambisome gilead copromoter fujisawa pay approximately fujisawa net revenue sale ambisome reserve right promote sell ambisome rest world pay fujisawa net revenue ambisome sale significant asian market include japan korea taiwan china india manufacture ambisome sell worldwide sell ambisome fujisawa sale price equal cost manufacture product sale canada price equal cost manufacture product plus specify percentage agreement fujisawa terminate patent cover ambisome japan expire glaxosmithkline april enter licensing agreement gsk give exclusive right commercialize hepsera solely treatment chronic hepatitis b asia latin america certain territory addition fee milestone payment contract revenue gsk require pay percentage revenue generate sale hepsera license territory agreement gsk enter clinical commercial supply agreement gsk require supply clinical commercial requirement fully burden cost subject reasonable forecasting order procedure agreement gsk expire individual country basis later patent expiration year commercial sale particular country addition gsk right electively terminate agreement month notice gilead subject fee elective termination circumstance early term agreement japan tobacco july enter licensing agreement japan tobacco japan tobacco obtain right commercialize product gilead hiv portfolio japan agreement include viread emtriva future coformulation product receive upfront fee entitle receive milestone payment japan tobacco require payment base product sale japan japan tobacco submit application viread expect submit application emtriva coformulation product japanese regulatory authority year contemplate license agreement december complete supply agreement japan tobacco supply japan tobacco viread emtriva future coformulation product osi pharmaceutical december sell osi pharmaceutical osi pipeline clinical stage oncology product relate intellectual property boulder colorado operation consideration asset receive osi million cash share osi common stock additionally osi require pay additional million cash combination cash osi common stock achievement osi certain milestone relate development nx advanced oncology product candidate separately manufacture agreement osi agree produce osi liposomal formulation product include nx manufacturing facility san dimas california pfizer enter agreement pfizer pharmacia corporation relate vistide agreement pfizer exclusive right market sell vistide country outside subject payment percentage net revenue require sell pfizer bulk vistide maintain vistide patent agreement pfizer expire individual country basis patent expiration year commercial sale country product cover patent addition pfizer terminate agreement month notice notice individual country basis month apply marketing approval competitive product roche enter collaboration agreement roche grant roche exclusive worldwide right tamiflu proprietary influenza neuraminidase inhibitor december receive license fee milestone payment roche total million relate executionof agreement regulatory filing approval tamiflu roche fund research development cost tamiflu include reimbursement million period january december agreement roche responsible pricing manufacturing promote sell tamiflu worldwide basis pay percentage net revenue sale tamiflu subject reduction certain define manufacturing cost agreement roche terminate individual country basis later patent expiration year commercial sale particular country addition roche right terminate agreement entirety individual country basis prior expiration time month notice sumitomo enter agreement sumitomo give sumitomo exclusive right develop market ambisome japan addition milestone payment sumitomo require pay percentage revenue generate japanese sale ambisome ambisome approve sale japan manufacture ambisome sale sumitomo japan price charge sumitomo supply ambisome percentage revenue required pay determined price ambisome japan agreement sumitomo terminate later patent expiration japan year commercial sale japan academic consulting relationship supplement research development effort regular business enter arrangement university medical research institution arrangement provide right patent patent application technology own institution return payment fee relate use right emory university university georgia research foundation inc emtricitabine april triangle obtain acquire acquisition triangle exclusive worldwide license emory universitys right purify form emtricitabine use hiv hepatitis b field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology year registration grant antihepatitis b product incorporate emtricitabine technology certain major market country hiv hepatitis b indication respectively triangle begin pay license maintenance fee development milestone achieve emory gsk settle litigation pende united states district court relate emtricitabine exclusive licensee foreign patent patent application file burrough wellcome co use emtricitabine treat hepatitis b license settlement agreement emory give access development clinical datum drug substance hold gsk relate emtricitabine emory gsk shire pharmaceuticals group plc shire settle worldwide patent dispute involve lamivudine emtricitabine term settlement emory receive exclusive license shire shire patent relate emtricitabine method use manufacture shire gsk receive exclusive license emorys patent relate lamivudine term license agreement emory automatically acquire exclusive sublicense shire patent relate emtricitabine grant term settlement resolve previously pende patent dispute emtricitabine license agreement emory terminate late patent expiration expiration obligation pay royalty addition right terminate agreement entirety respect indication hiv hbv country prior expiration time day notice amdoxovir march triangle enter acquire acquisition triangle license agreement emory university georgia research foundation inc ugrf pursuant receive exclusive worldwide license emorys ugrfs right series nucleoside analogue include amdoxovir dxg ie active antihiv agent use hiv hepatitis b field march triangle begin pay license maintenance fee development milestone achieve january announce intent terminate license agreement amdoxovir md anderson cancer center enter agreement md anderson cancer center relate hepsera agreement currently pay md anderson cancer center percentage net revenue base sale hepsera agreement md anderson cancer center terminate later patent expiration year commercial sale iocbrega enter agreement iocbrega relate viread hepsera vistide agreement receive iocbrega exclusive right manufacture use sell nucleotide compound cover agreement currently pay percentage net revenue base sale viread hepsera vistide iocbrega agreement iocbrega terminate individual country basis later patent expiration year commercial sale addition iocbrega terminate license particular product key market absence commercial sale product month regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation technology hold company university colorado boulder relate selex technology identify aptamer arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi certain variable royalty base revenue generate sale product derive selex technologydeveloping world collaboration bill melinda gates foundation family health international october enter agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi fund million threeyear grant gates foundation dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart trial development antiretroviral therapy africa aim study clinical versus laboratory monitoring practice structure treatment interruption versus continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis clinical trial conduct institute world health partnership world health organization international distribution agreement distributor europe asia latin america middle east africa grant distributor exclusive right sell viread emtriva hepsera ambisome particular country country specify period time agreement provide collaborative effort distributor obtain regulatory approval product particular country marketing product country agreement establish price distributor pay product require deliver quantity product order distributor manufacture ambisome manufacture ambisome commercial quantity separate adjacent facility san dimas california medicines control agency united kingdom fda approve commercial production ambisome facility produce import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union discontinued manufacturing daunoxome use commercially available material equipment manufacture product currently obtain amphotericin b cholesterol use manufacture ambisome single approve supplier ambisome sell freezedrie product currently freezedry ambisome san dimas manufacturing facility use party freezedry additional product need give current projection ambisome demand believe sufficient capacity meet future demand option instal additional freezedrying capacity san dimas additional supply necessary unable install additional freeze drying capacity san dimas locate appropriate party meet need ability meet increase ambisome demand diminish antiviral product contract party manufacture antiviral drug clinical commercial purpose include viread emtriva hepsera vistide manufacture viread tablet single contract manufacturer european union sale distribution territory addition second contract manufacturer europe european union distribute product approve respective agency obtain qualification european union contract manufacturer adefovir dipivoxil active ingredient hepsera contract manufacturer final hepsera drug product commercial supply seek qualify second supplier enter agreement abbott laboratories abbott manufacture emtricitabine bulk drug substance final drug product qualified second contract manufacturer bulk drug substance european union supplier approve fda european union manufacture cidofovir bulk drug substance vistide single fda emea approve supplier vistide drug product january roche announce production problem liquid suspension form tamiflu approve treatment child young yearold available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem november chugai announce recall tamiflu problem japan reduce net sale royalty roche royalty roche tamiflu expectation date production commercialization issue material effect earning expect material effect earning future commercialscale manufacturing facility antiviral product future antiviral product need develop additional manufacturing capability establish additional party supplier order manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct largescale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture ourproduct compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable believe compliance material environmental regulation relate manufacture product patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date europe primary patent patent issue pende application cover compound market product product candidate patent expiration european patent expiration product viread hepsera ambisome tamiflu vistide emtriva patent cover viread hepsera vistide emtriva hold party acquire exclusive right patent agreement party collaborative relationship academic consulting relationship patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form hepsera china certain asian country application pende asian country include china relate specific form formulation hepsera asia major market hbv therapy obtain patent compound year obtain marketing approval limit time prevent company develop compound reduce value product apply patent term extension example extension patent vistide grant number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time include patent issue pende patent application patent eventually issue prevent develop sell certain product obtain license use patent technology patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention competition product development program target number disease condition include viral fungal infection commercially available product disease large number company institution spend considerable amount money resource develop additional product treat disease current product compete available product base primarily efficacy safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose product market future compete product offer competitor competitor introduce datum show improved characteristic product improve increase marketing effort simply low price product sale product decrease certain product develop future compare favorably product offer competitor exist future product compare favorably new product develop competitor ability competitive depend ability attract retain qualified personnel obtain patent protection develop proprietary product process secure sufficient capital resource substantial period take develop product viread emtriva hiv competitive landscape crowd complicated treatment trend continue evolve grow number antihiv drug currently sell advance stage clinical development brand drug available zerit stavudine dt sell bristolmyer squibb bms fix combination product combivir azt tc trizivir azt tc abc sell gsk represent direct competition viread company process launch formulation exist drug indicate fda oncedaily oral dosing include gsk mg dose epivir tc bmss new extend release formulation zerit recently approve antiretroviral product include atazanivir qd protease inhibitor bms fuzeon injectable integrase inhibitor rochetrimeris gsk file application approval oncedaily dose ziagen abacavir new fix dose combination ziagen epivir company compete hiv therapeutic category pfizer merck boehringeringelheim abbott ambisome ambisome face strong competition current expect competitor current competitor include conventional amphotericin b bms numerous generic manufacturer caspofungin product develop merck market cancida caspofungin voriconazole develop pfizer market vfend lipidbase amphotericin b product approve europe include abelcet sell enzon corp canada japan medeus pharma ltd europe amphotec sell intermune pharmaceutical inc presently unapproved expect competitor include class treatment call echinocandin include fujisawa micafungin receive marketing approval japan october review regulatory approval canada anidulafungin vircuron inc versicor inc product candidate evaluate multiple latestage clinical trial finally schere plough develop noxafil posaconazole currently phase trialscompetition current expect competitor erode likely continue erode revenue receive sale ambisome hepsera hepsera face significant competition exist therapy treat patient infect hbv significantly epivirhbv lamivudine develop gsk collaboration shire pharmaceutical sell major country north south america europe asia orally administer nucleoside analogue inhibit hbv dna polymerase introna interferon alfab sell schere plough major country north south america europe asia introna injectable drug immunomodulatory effect hepsera face competition clinicalstage candidate include bristolmyer squibb entecavir idenixs ldt oral nucleoside analogue currently phase trial competition include roche pegasys pegylate interferon alfaa currently study chronic hepatitis b tamiflu tamiflu competes relenza antiflu drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder vistide vistidecompete number drug treat cmv retinitis include ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valganciclovir market roche foscarnet intravenous drug sell astrazeneca formivirsen drug inject directly eye sell cibavision number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product government regulation operation activity subject extensive regulation numerous government authority countrie drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product developmentand product approval process expensive time consume fda approve drug sell general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential safety benefit submit datum fda investigational new drug application ind seek approval test compound human clinical trial fda accept investigational new drug application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase clinical trial fda approval process believe datum phase clinical trial adequate level safety effectiveness file new drug application nda fda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question drug committee make recommendation fda bind fda generally follow fda fda agree compound require level safety effectiveness particular use allow sell drug use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require complete additional testing provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine new drug application contain adequate evidence safety benefit drug addition fda approve drug limit use drug approval withdraw fda believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug manufacturing facility drug sell include company manufacture drug approve fda subject periodic inspection fda foreign establishment manufacture product sell approve fda subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug designate fast track product fda eligible priority month review accelerate approval case viread drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside european union centralize approval procedure authorize marketing product country european union include major country europe procedure decentralized system approval country european union obtain approval country european union simplify application process approval centralized procedure pricing reimbursement approval require country vistide viread hepsera emtriva approve european union centralize procedure viread hiv drug review accelerate approval european union hepsera receive traditional review emtriva pricing reimbursement insurance company health maintenance organization hmos thirdparty payor government seek limit charge drug example certain foreign market pricing negotiation require obtain approval product expect continue number federal state proposal implement drug price control addition manage care organization common continue seek low drug price announcement proposal effort cause stock price decrease proposal adopt revenue decrease ability sell drug depend availability reimbursement government private insurance company government insurance company demand rebate predetermine discount list price expect product develop particularly aid indication subject reimbursement issue certain product obtain regulatory approval reimburse governmentand insurance company regulatory approval price generally require foreign country particular certain country condition approval product agreement seller sell product certain price country past require price reduction connection product approval certain regulatory authority future establish low price regulatory action reduce price product country practical effect require reduce price country european government notably germany italy implement consider legislation require pharmaceutical company sell product subject reimbursement mandatory discount mandatory discount reduce revenue receive drug sale certain develop country significantly affect hiv aids parallel import generic competition occur adversely affect revenue sale market share viread employee february approximately fulltime employee believe good relation employee website website address wwwgileadcom available free charge website annual report quarterly report form q current report form k director officer section report amendment report soon reasonably practicable filing provide hyperlink edgar website directly report risk factor affect gilead evaluate business carefully consider follow risk addition information report follow risk materially adversely affect business operating result financial condition substantially revenue derive sale product unable maintain continue grow sale viread maintain sale ambisome result operation adversely affect currently dependent sale lead product viread ambisome support exist operation product account approximately total revenue year end december unable continue grow viread revenue maintain ambisome sale result operation likely suffer need scale operation viread product sale year end december million total revenue ambisome product sale royalty year end december million total revenue able maintain growth rate viread current sale level ambisome reason state risk factor section particular follow reason face significant competition business substantially great resource example experience decline sale volume ambisome introduction new european competitor volume basis ambisome sale decrease europe compare viread ambisome long period time additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning label narrow approve indication halt sale product reduce revenue product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price example authority germany italy reduce reimbursement provide patient viread expect similar reduction france fail commercialize new product expand indication exist product prospect future revenue stock price adversely affect introduce new product increase revenue exist product able grow revenue order expand product begin market hepsera treatment chronic hepatitis b emtriva treatment hiv united states european union addition develop coformulation tenofovir emtricitabine failure achieve objective expect material adverse effect business result operation able achieve objective follow reason hepsera new drug face competitive marketplace experience establish competitor example hepsera primarily compete lamivudine united states interferonalfa b european hepatitis b market hepseras primary advantage lamivudine patient far likely develop resistance hepsera lamivudine lamivudine market long hepsera lamivudine resistance problem surface product market hepsera continue superior resistance property lamivudine hepsera primary advantage interferonalfa b great safety tolerability oral dose new version interferon pegylatedinterferon development prove safe tolerable offer onceweekly injectable dose marketing treatment hepatitis b difficult infected individual diagnose consensus physician appropriate method treatment physical combination emtricitabine tenofovir technically feasible costeffective addition able develop chemistry manufacture bioequivalence package show coformulated tablet give exposure tenofovir emtricitabine drug give individually support regulatory approval complete stability study necessary support approval coformulation tenofovir emtricitabineif fail increase sale hepsera obtain regulatory approval successfully market coformulation emtricitabine tenofovir able increase revenue expand research development effort significant safety issue arise market product sale decline adversely affect result operation datum support marketing approval product include viread ambisome hepsera emtriva form basis safety warning product label obtain control clinical trial limit duration case viread limited postapproval use follow approval product long period time patient take numerous medicine underlie health problem monitor dose compliance new safety issue report postmarkete use rule contributory role product required provide additional warning label narrow approve indication reduce market acceptance product example observe kidney toxicity clinical trial viread kidney toxicity report postapproval use viread viread label update include warn safety issue market product arise sale product halted regulatory authority discontinue development adefovir dipivoxil mg treatment hiv infection concern kidney toxicity arise study mg dose adefovir dipivoxil hepsera associate significant kidney toxicity clinical trial date patient preexist kidney problem take drug know cause kidney toxicity kidney toxicity develop broad hepatitis b patient population operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay commercialization product product develop approve marketing sale regulatory authority subject extensive regulation fda comparable regulatory agency country continue clinical trial ambisome viread hepsera emtriva currently approve additional use anticipate file marketing approval additional country additional product year product fail receive marketing approval timely basis current filing strategy coformulation tenofovir emtricitabine base datum complete study fda require additional pivotal study combination product regulatory filing delay regulatory authority outside european union approve emtricitabine treatment hiv sufficient efficacy advantage currently market lamivudine product able obtain regulatory approval necessary expand commercial effort new market failure delay limitation regulatory change action recall delay commercialization product adversely affect result operation addition market product sell product subject extensive regulation review later discovery previously unknown problem product problem promotional activity result restriction product include withdrawal product market example august fda issue write warning concern promotional activity viread fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution addition name multiparty lawsuit allege inflate reimbursement rate medicaid program certain pharmaceutical manufacture result clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product number company industry suffer setback advance clinical trial despite promise result early trial example fda deny approval adefovir dipivoxil mg drug develop gilead treatment hiv base concern kidney toxicity future seek clinical development similar compound potential kidney toxicity adverse effect product development fail achieve primary endpoint clinical trial safety issue arise commercialization drug candidate delay halted manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis party fail perform require impair ability deliver product timely basis cause delay clinical trial application regulatory approval event harm competitive position manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation fdas current good manufacturing practice extensive regulation govern manufacturing process stability testing recordkeeping quality standard addition manufacturing operation subject routine inspection regulatory agency similar regulation effect country viread hepsera vistide emtriva rely party manufacture bulk drug substance final drug product clinical commercial purpose addition roche responsible manufacturing tamiflu thirdparty manufacturer develop problem control problem adversely affect business example january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche manufacture ambisome facility san dimas california formulation manufacturing facility manufacturing facility ireland perform certain quality control testing labeling packaging addition use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need able obtain material necessary manufacture product limit ability generate revenue material utilize operation facility example depend single supplier high quality amphotericin bdistearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supplier key component material name new drug application file fda product significant delay occur qualification new supplier require supply supplier interrupt reason unable ship viread ambisome hepsera emtriva vistide supply product development clinical trial need develop additional manufacturing capacity exist future product increase expense evaluate past continue evaluate feasibility acquire manufacturing capability support production product principally viread emtriva facility require increase production capacity order support clinical trial produce product commercial sale acceptable cost manufacture product past develop technological capability building purchasing facility increase expense guarantee able recover investment manufacturing capability depend relationship company sale marketing performance revenue failure maintain relationship negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance include collaboration fujisawa sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide japan tobacco viread emtriva certain country rely international distributor sale ambisome viread emtriva european country intend rely international distributor sale hepsera relationship involve clinical development product partner reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product include viread emtriva hepsera ambisome tamiflu decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan korea success hepsera territory depend entirely effort gsk regard gsk promote epivirhbv product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbv receive royalty gsk equal percentage net sale gsk gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera substantially reduce expense associate clinical trial sale fluctuation result inventory level hold wholesaler cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter uneven unexpected spending program cause operating result fluctuate quarter quarter addition substantial portion sale activity united states conduct distributor amerisource bergen corp mckesson corp cardinal health inc inventory level hold wholesaler fluctuate significantly cause sale result operating result fluctuate unexpectedly quarter quarter example base review ndc prescription trend im inventory datum actual viread sale believe quarter end june wholesaler build inventory level estimate month believe inventory buildup follow equivalent possibly great inventory reduction quarter end september approximately half product sale occur outside currency fluctuation cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar equivalent sale negatively impact financial condition result operation use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collected additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable use forward contract reduce impact foreign currency fluctuation future result effort successful fluctuation adversely affect result operation face credit risk european customer adversely affect result operation particularly subject credit risk european customer european product sale government own support customer greece spain portugal italy subject significant payment delay government funding reimbursement practice account receivable fromgovernment own support customer country total million december significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect plan supply viread cost certain develop country expose liability material adverse affect result operation financial condition launch distribution program pursuant supply viread cost country africa country designate develop country united nations supply distribution drug resourcepoor environment complicated undertaking program develop face unforeseen challenge risk rise unforeseen liability example patient develop country viread closely supervise doctor develop nation accordingly increase likelihood viread relate complication go undetected untreated result significant liability gilead product revenue reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly viread agree provide cost country africa country designate develop country united nations revenue adversely affect addition european union require permit cross border sale allow buyer country governmentapprove price product relatively high purchase product legally country sell low price additionally consumer able purchase product include hiv medicine internet pharmacy country substantial discount crossborder sale adversely affect revenue country require grant compulsory license hiv product face generic competition hiv product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company hiv drug available low cost patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale product country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version product country reduce sale respond governmental concern reduce price product addition reduce sale compulsory license increase risk counterfeiting long control manufacture distribution market addition country canada consider amend patent law permit export patent product country develop world situation result operation adversely affect exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide significant percentage sale viread hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary recently pass congress additionally state enact health care reform legislation federal state development possible result operation adversely affect future health care reform europe success hepsera tamiflu emtriva viread depend largely obtain maintain government reimbursement european country include united kingdom france patient reluctant pay prescription drug pocket expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis addition international market government control price prescription pharmaceutical market regulatory marketing approval receive pricing negotiation governmental authority month long foreign government pass consider legislation require sell product subject reimbursement mandatory discount sale compete product attempt gain market share introductory pricing program competitor require low price country adversely affect result operation able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right right foreign issue patent file continue file patent application abroad relate technology risk patent issue application patent sufficient protect technology patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera application pende asian country relate form formulation adefovir dipivoxil asia major market therapy hepatitis b indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale commercial value product limit addition patent provide adequate protection certain country africa asia include china competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use viread ambisome hepsera emtriva tamiflu vistide product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company maintain product liability insurance successful product liability claim cover insurance require pay amount provide insurance impair financial condition ability clinically test market product item property corporate headquarters include principal executive office research facility locate foster city california location approximately square foot space proximately locate building currently occupy building tenant occupy remain building occupy facility san dimas california location lease approximately square foot space house research development activity manufacture certain administrative function lease expire november renewal option present addition lease adjacent warehouse facility square foot space use product distribution administrative function lease expire additional fiveyear extension durham north carolina lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire october gilead option renew sevenyear term addition lease approximately square foot space sale market regulatory finance information technology human resource operation europe australia include prepaid year lease square foot manufacturing distribution facility ireland lease expiration date believe facility adequate suitable current nearterm future need item legal proceeding september gilead enter settlement agreement release university license equity holdings inc ulehi archemix corporation concern right identify aptamer selex technology license ulehi gilead settlement agreement release resolve dispute party arise gilead assignment right identify certain aptamer archemix september county westchester new york westchester serve gilead complaint file united states district court southern district new york allege gilead large number pharmaceutical manufacturer defendant report price product overstate average wholesale price awp allegedly inflate reimbursement rate medicaid program cause westchester pay artificially inflate price cover drug include case gilead viread addition westchester argue defendant include gilead accurately report good price medicaid program complaint assert vary claim federal rico statutes state law corollary state law claim deceptive trade practice common law fraud gilead intends vigorously defend allegation complaint seek undetermined damage relief include declaratory injunctive relief defendant lawsuit name numerous lawsuit comparable awp allegation knowledge gilead name lawsuit gilead name serve lawsuit comparable awp allegation adverse result result material damage purport class action complaint file november united states district court northern district california gilead company chief executive officer chief financial officer executive vice president operation research development senior vice president manufacture research complaint allege defendant violate federal security law specifically section b securities exchange act rule b securities exchange commission make certain allege false misleading statement plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december believe meritorious defense allegation contain complaint intend defend case vigorously trial date schedule february court issue order appoint lead plaintiff action lead plaintiff march file consolidate complaint december purport shareholder derivative lawsuit file individual shareholder behalf gilead director certain executive officer superior court state california county san mateo allege thing defendant violate california corporations code breach fiduciary duty owe gilead gilead name nominal defendant plaintiff seek unspecified damage behalf gilead connection allege insider trading period july october defendant allege breach fiduciary duty abuse control waste mismanagement case consolidate single action january plaintiff file consolidated complaint february trial date schedule intend appropriate action defend interest connection litigation party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position item submission matter vote security holder matter submit vote security holder quarter end december ii item market registrant common stock relate stockholder matter common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception anticipate pay foreseeable future december issue million convertible senior note december private offer goldman sachs co resold note qualified institutional investor note currently convertible total share common stock share net proceed approximately million item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue inprocess research development total cost expense income loss operation gain sale oncology asset provision benefit income taxis income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute gilead sciences inc select consolidated financial datum continue thousand december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible debt accumulate deficit total stockholder equity gilead complete acquisition net asset triangle aggregate purchase price million approximately million purchase price allocate inprocess research development record income tax benefit million relate reduction valuation allowance certain net defer tax asset sell share osi common stock recognize loss sale marketable security million share partial consideration sale oncology asset complete sale oncology asset relate technology osi pharmaceuticals inc record nonoperate gain million record nonoperate gain million sale percent interest proligo gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedge activitiesin quarter change account change accounting principle effective quarter gilead adopt secs staff accounting bulletin sab revenue recognition financial statement change account change accounting principle cash dividend declare pay common stock item management discussion analysis financial condition result operation executive summary biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company revenue approve product marketing operation country focus research clinical program antiinfective currently market viread tenofovir disoproxil fumarate emtriva emtricitabine treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent vistide cidofovir injection treatment cmv retinitis roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement december decision discontinue sell daunoxome daunorubicin citrate liposome injection drug approve treatment kaposis sarcoma seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquisition asset triangle pharmaceuticals inc complete january internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop clinical stage product treat hiv infection chronic hepatitis b operating result comparison characterize solid growth key hiv drug viread represent second consecutive year significant increase total product revenue base independent party datum viread widely prescribe antiretroviral class drug achieve new total prescription compete drug nucleotidenucleoside reverse transcriptase inhibitor nrti market result growth viread sale higher expect ambisome sale control spending generate positive cash flow operation year increase million million year year growth expect hiv drug sale grow near term expect slow rate experience past year enable growth increase importance oncedaily regimen prescribe hiv medication availability viread emtriva acquire triangle provide physician ability construct daily regimen operating result impact acquisition asset triangle january complete acquisition expand antiviral pipeline triangle development stage company particular focus potential therapy hiv include aids hepatitis b virus hbv aggregate purchase price million include cash pay million outstanding stock fair value stock option assume million estimate direct transaction cost million employee relate cost million approximately million purchase price allocate process research development represent fair value triangle incomplete research development program reach technological feasibility alternative future use acquisition date result transaction relate inprocess research development charge operate loss million versus operate income million acquisition important compound acquire opportunity provide create coformulation viread emtriva single pill dose day successful expect coformulated product grow hiv franchise note consolidated financial statement information triangle acquisitionin december complete sale oncology asset osi pharmaceuticals inc transaction value million cash osi stock transaction allow focus continue strengthen core expertise infectious disease note consolidated financial statement information certain prior period amount reclassify conform current presentation forwardlooke statement risk factor follow discussion contain forwardlooke statement involve risk uncertainty read risk factor affect gilead factor cause contribute material difference forwardlooke statement actual result risk factor discussion read conjunction consolidated financial statement note include report critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance accounting principle generally accept united states preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense income taxis contingency base estimate historical experience marketspecific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement record estimate reduction revenue expect return expire product government rebate program medicaid reimbursement customer incentive cash discount prompt payment estimate government rebate program cash discount base contractual term historical utilization rate expectation future utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern include monitor feedback receive sale force customer use satisfaction purchase thirdparty datum assist monitor channel inventory level subsequent prescription new product review long shelf life product sell similar channel monitor activity clinical trial key competitor assess potential impact future sale return expectation necessary expect return market drug generally low shelf life product range month viread month ambisome condition competitive market serve drug circumstance change action increase product return estimate offer additional customer incentive result incremental reduction future revenue time return estimate change incentive offer example increase reserve government discount viread sale result review historical utilization rate impact midyear price increase viread similar increase future base continued review utilization rate potential price increase viread maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account write inventory base historical review quantity raw material bad batch experience give year expectation production inventory level perform quality control review individual raw material batch generally maintain inventory reserve base estimate obsolescence risk competition primarily shelf life product long current assumption future production inventory level demand competition change actual market condition favorable project management additional inventory reserve require negatively impact product gross margin record accrual estimate clinical preclinical study cost clinical preclinical study perform party contract research organization cro cost significant component research development expense incur million million million respectively cro cost accrue cost clinical study perform cro straightline basis term service period adjust estimate require base ongoing review level effort actually incur cro initially estimate work perform contract occur ratably period expect milestone event total contract completion date expect completion date estimate base term contract past experience similar contract estimate match actual service perform organization determine patient enrollment level measure activity specify contract result validate accrual quarterly write vendor confirmation detail review activity perform contract base result validation process assess appropriateness accrual adjustment deem necessary expense reflect actual effort incur cro generally significant portion total cost associate start activity trial patient enrollment gilead extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management budget basis cost typically total contract value actual basis percentage range significantly wider contract expand contract scope compare original budget startup cost particular trial change significantly startup cost usually occur month contract establish milestone event drive nature remain activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix price vary length month single dose phase study year complex phase study average length contract upper end range order provide long term safety efficacy datum support commercial launch viread hepsera emtriva throughdecember understate overstate activity level particular study material adjustment require material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant research development expense future period develop income tax provision include defer tax asset liability base significant management judgment record valuation allowance reduce defer tax asset likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance determine able realize certain defer tax asset relate valuation allowance adjustment defer tax asset increase income period determination adjustment fourth quarter determine likely certain defer tax asset realize release related valuation allowance result income tax benefit approximately milion likewise determine able realize defer tax asset future adjustment defer tax asset charge income period determination evaluate realizibility defer tax asset quarterly basis future effective tax rate affect factor change tax law rate change interpretation law overall change future level earning research development capital spending management discuss development selection critical accounting policy audit committee gilead board director audit committee review disclosure present relate result operation total revenue total revenue million million million include total revenue net product sale royalty revenue contract revenue include revenue research development rd manufacturing collaboration product sale consist follow thousand product sale change change viread ambisome total product sale product sale increase compare primarily significant increase sale viread hiv approve sale october european union february antiretroviral therapy widely prescribe physician significant percentage product sale continue denominate foreign currency prior hedge exposure impact fluctuate foreign exchange rate forecast sale january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency reduce eliminate fluctuation sale change foreign currency exchange rate loss revenue hedge reduce product revenue million million sale viread total product sale compare total product sale total product sale viread sale million sale increase versus million international sale increase versus continue market expansion viread expect viread sale grow approximately range million million experience significant fluctuation distribution channel inventory level speculative purchase major wholesaler result experience increase quarter quarter sale volatility purchase pattern enact certain policy reduce type purchasing discussion key wholesaler expect continue experience sale volatility foreseeable future prior revenue primarily derive sale ambisome represent total product sale total product sale ambisome sale million high favorable currency environment compare volume basis ambisome sale europe decrease compare increase competition exclude impact foreign currency relative dollar ambisome sale grow increase sale compare primarily volume sale increase europe offset decline sale expect increase competition expect ambisome sale low range million million royalty revenue record royalty revenue million compare million million threeyear period significant source royalty revenue sale ambisome fujisawa copromotion arrangement royalty revenue fujisawa million compare million million record royalty revenue million million million relate sale tamiflu begin recognize royalty tamiflu quarter june roche receive european regulatory approval tamiflu treatment influenza adult child prevention adolescent adult difficult estimate party product sale record royalty revenue quarter arrear lag reporting royalty relate severe flu epidemic fourth quarter record quarter contract revenue total contract revenue million compare million million primary source contract revenue licensing selex process patent estate archemix collectibility concern recognize cash receive thisprovide contract revenue million million roche milestone payment million european prophylaxis treatment approval tamiflu million milestone payment relate development tamiflu rd collaboration agreement december entitle additional milestone payment million roche achieve certain developmental regulatory milestone april gilead gsk enter licensing agreement provide gsk right commercialize hepsera antiviral treatment chronic hepatitis b asia latin america certain territory agreement gilead retain right hepsera canada eastern western europe australia new zealand gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china korea japan taiwan gsk pay upfront licensing fee million pay additional million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera september million receive canadian approval hepsera august gsk pay royalty net sale hepsera gsk territory gsk responsibility development commercialization hepsera gsk territorie million upfront fee million approval milestone fee record defer revenue total million million recognize contract revenue respectively million balance defer revenue december amortize contract revenue period remain obligation agreement approximately year december complete sale oncology asset osi date receive million cash million osi stock sale agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal product include sale manufacturing facility san dimas california recognize million million respectively contract revenue manufacturing agreement october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million record net amount million million contract revenue respectively require license agreement ulehi pay million million payment ulehi receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant ulehi time transfer remainder warrant ulehi march enter agreement eyetech pharmaceuticals inc relate proprietary aptamer eye currently know macugen currently phase clinical trial macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product eyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue million recognize revenue entitle additional cash payment eyetech million eyetech reach certain macugen development milestone additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor january eyetech complete initial public offering intend exercise warrant share common stock sell share subject day lockup period fair value warrant adjust quarter result eyetech public offering cost good sell follow table indicate cost good sell thousand change change cost good sell substantially increase year year period attribute increase volume viread sell product launch late quarter gross margin product gross margin compare improvement primarily drive product mix viread high margin product contribute significantly net product sale succeed year movement foreign currency exchange rate impact gross margin price product currency country product sell significant majority manufacturing cost dollar example increase value foreign currency relative dollar positively impact gross margin manufacturing cost remain approximately revenue translate dollar increase gross margin positively impact weaken dollar gross margin negatively impact factor forward contract hedge percentage forecast international sale reduce impact change foreign currency exchange rate gross margin potential impact unpredictable uncontrollable change exchange rate relative dollar mix product sale viread hepsera ambisome expect gross margin remain relatively stable compare research development expense rd expense total cost expense exclude purchase inprocess research development expense total rd expense million compare million million major component rd expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis follow table break research development expense major component thousand change change research clinical development pharmaceutical development oncology divest total million increase rd spending versus attributable increase headcount clinical trial associate development emtriva coformulation viread emtriva addition settle contractual dispute vendor result reimbursement million record research development expense expect rd expense approximately million million approximately high expense primarily cost associate development fixeddose combination viread emtriva million decrease rd spending compare primarily reduction expense associate clinical program viread approve fda sale october elimination expense associate oncology program result sale program osi december additionally recognize expense million million upfront license fee pay cubist pharmaceutical relate european licensing agreement daptomycin know cidecin sign january termination agreement september record million rd expense represent remain unamortized asset relate preclinical oral formulation daptomycin industry report indicate biopharmaceutical company generally take year average year research develop bring market new prescription medicine average generally consistent project develop internally recent product development timeline accelerate basis drug development process include step define fda process begin file ind successful allow opportunity clinical study potential new medicine clinical development typically involve phase study phase generally account average seven year drug total development time significant cost associate clinical development phase trial tend long large study conduct drug development process currently product development phase study successful development product highly uncertain completion date rd expense vary significantly product difficult predict successful development fda approval product undertake additional study try expand product label market potential complete discussion risk uncertainty associate complete development product risk factor affect gilead section item sell general administrative expense follow table highlight sell general administrative expense thousand change change sell general administrative increase expense compare primarily global sale marketing effort include expansion european sale force increase infrastructure investment require support growth business increase expense compare primarily global sale marketing effort include expansion european sale force support commercial launch viread hepsera expect sga expense approximately million million high level primarily increase marketing activity associate continued promotion viread emtriva hepsera ambisome inprocess research development connection acquisition net asset triangle complete january record inprocess research development expense million quarter charge triangle incomplete research development program reach technological feasibility alternative future use acquisition date remain effort completion triangle research development project primarily consist clinical trial cost length success extremely difficult predict numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain emtricitabine treatment chronic hepatitis b purchase triangle approve european union marketing approval significant limitation use terminate right respect potential product acquire acquisition triangle approval fixeddose combination product contain tenofovir df emtricitabine future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product development successfully commercialize emtriva example product similaritie exist product result difficult successfully penetrate market achieve significant revenue addition emtricitabine treatment chronic hepatitis b face significant uncertainty associate pricing efficacy cost produce successfully resolve result strategic decision discontinue development product clevudine amdoxovir believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact value acquire inprocess research development determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintiesin develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market asset impairment record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment noncash charge drive decision december terminate liposomal research development activity san dimas discontinue daunoxome product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value long live asset estimate fair value gain sale oncology asset december complete sale oncology asset pipeline clinical stage oncology product relate intellectual property boulder colorado operation include clinical research drug development personnel infrastructure facility osi pipeline clinical candidate include nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor closing date receive million cash osi common stock value approximately million record nonoperating gain million income taxis million fourth quarter result transaction loss sale marketable security july sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million year end december gain sale unconsolidated affiliate august sell percent interest proligo llc proligo degussa corporation million cash proligo joint venture skw americas inc focus manufacturing oligonucleotide skw americas subsidiary degussa corporation hold remain percent proligo proceed net investment proligo reflect million gain sale unconsolidated affiliate interest income net record interest income million compare million million decrease compare attributable significant decline interest rate low average cash balance acquisition net asset triangle purchase foster city campus partially offset positive cash flow operation decrease compare attributable significant decline interest rate partially offset high average cash balance positive cash flow operation proceed sale oncology asset osi interest income depend principally prevail interest rate control level cash cash equivalent marketable security balance interest expense incur interest expense million compare million million significant increase year interest million convertible senior note issue december interest expense consist primarily interest million convertible subordinate note convert common stock december expect interest expense decrease compare primarily redemption million convertible subordinate note december provision benefit income taxis provision benefit income taxis million million million respectively benefit include reversal valuation allowance certain defer tax asset december conclude likely realize portion benefit relate defer tax asset accordingly reduce valuation allowance asset record tax benefit million recognition defer tax asset impact current period cash flow recognition defer tax asset increase report earning share result benefit record statement operation reduction valuation allowance partially offset tax benefit record income tax expense associate income earn foreign subsidiary foreign loss low rate nontax deductibility purchase inprocess research development charge significant net operating loss reduce liability exclude benefit relate reversal valuation allowance write purchase inprocess research development effective tax rate expect effective tax rate range year reflect normalize tax rate go forward income tax expense primarily associate income earn foreign subsidiary significant net operating loss reduce tax liability significant increase income tax expense result principally gain sale oncology asset osi record approximately million federal state alternative minimum taxis provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million equity loss unconsolidated affiliate record million equity loss unconsolidated affiliate proligo sell percent interest august cumulative effect change accounting principle adopt sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle million note consolidated financial statement discussionliquidity capital resource cash cash equivalent marketable security total million december million december decrease million primarily acquisition triangle net cash impact million purchase foster city campus million major source use cash include net cash provide operation million proceed issuance stock employee stock plan million partially offset additional capital expenditure million work capital december million compare million december significant change working capital include million increase account receivable million increase inventory million increase current defer tax asset account receivable increase primarily increase sale viread europe million increase inventory primarily increase purchase raw material production viread inventory meet increase sale demand million increase current defer tax asset reversal valuation allowance certain net defer tax asset million increase account payable primarily increase raw material purchase support viread sale growth significant change current liability include million increase accrue liability significant component million increase accrue liability exclusive assume liability associate acquisition net asset triangle consist million increase accrue liability million increase accrue compensation employee benefit partially offset million decrease accrue clinical preclinical expense million increase accrue liability primarily medicaid rebate obligation associate high sale viread increase income taxis payable increase record liability associate fair value forward currency contract million increase accrue compensation primarily increase bonus accrual expansion sale force million decrease accrue clinical preclinical expense primarily decrease activity associate clinical trial program viread hepsera addition purchase foster city campus capital expenditure million compare million million expenditure primarily facility improvement accommodate growth laboratory manufacturing equipment capital expenditure relate research development million spend million spend million spend expect capital spending million million increase infrastructure need high rd spending associate pilot plant construct foster city facility december issue million convertible senior note december private offering note currently convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note december issue million convertible subordinated note december private offering note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date gilead call million convertible subordinate note redemption november convert gilead common stock december conversion million remain balance relate debt issuance cost reclassify additional pay capital believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance current future product progress scope research development effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense cost associate noprofit global access program develop nation possibility acquire manufacturing capability office facility possibility acquire company new product establishment additional collaborative relationship company future require additional funding form proceed equity debt financing universal shelf registration filing december potential issuance million security additional collaborative agreement corporate partner fund require assure available favorable term subsidiary establish variety subsidiary country purpose conduct business location subsidiary consolidate financial statement special purpose entity unconsolidate financial statement involve nonexchange trade commodity contract account fair value commercial commitment relate party employee loan contractual obligation contractual obligation form capital operating lease note payable raw material supply arrangement clinical research organization contract follow table summarize contractual obligation thousandspayment period contractual obligation total year year year year longterm debt obligation capital lease obligation operating lease obligation capital commitment inventory purchase obligation clinical trial total december firm capital project commitment approximately million relate chemical development pilot plant currently construction foster city facility budget capital expenditure significantly higher anticipate increase capital spending future year december firm commitment purchase inventoryrelate material amount disclose represent minimum purchase requirement actual purchase differ significantly amount december clinical study clinical trial phase significant expenditure contract research organization contract cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification exist contract anticipate potential new contract recent accounting pronouncement january fasb issue fasb interpretation fin consolidation variable interest entity interpretation arb fin require certain variable interest entity consolidate primary beneficiary entity equity investor entity characteristic control financial interest sufficient equity risk entity finance activity additional subordinate financial support party fin effective immediately new variable interest entity create acquire january create acquire new variable interest entity january variable interest entity create acquire prior february provision fin amend apply end interim annual period end march adoption fin material impact consolidate financial statement item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity sale activity europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business mitigate impact change currency exchange rate cash flow foreign currency sale transaction enter foreign exchange forward contract hedge foreign currencydenominate account receivable additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior hedge exposure impact fluctuate foreign exchange rate forecast sale january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand fair value currency notional average rate december british pound euro total notional million fair value million open foreign exchange forward contract december compare total notional million fair value million open foreign exchange forward contract december significant increase outstanding contract attribute decision expand time horizon include month month hedging forecast international sale decision growth international business increase fluctuation exchange rate primarily euro interest rate risk portfolio availableforsale investment security fixedrate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestbeare asset fixedrate liability december dollar thousand fair value year end december december total asset availableforsale security average interest rate liability longterm obligation include current portion average interest rate convertible senior debenture interest rate longterm obligation consist capital lease operating lease net noncancelable sublease interest portion payment include international credit risk account receivable balance december million compare million december growth primarily high product sale viread europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe account receivable balance reflect consolidated balance sheet include customer country collectible perform credit evaluation customer financial condition generally require collateral item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define sec rule control procedure company design ensure information require disclose company report file securities exchange act exchange act record process summarize report require time period base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statement heading nominee executive officer board director audit committee compliance section securities exchange act item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee reportitem security ownership certain beneficial owner management information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading compensation committee interlock insider participation certain transaction executive compensation item principal accountant fee service information require item incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statement heading independent accountant iv item exhibit financial statement schedule report form k follow document file index list financial statement report ernst young llp independent auditor audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit description footnote number document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc wholly own subsidiary registrant triangle pharmaceutical inc date december amend restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc agreement plan merger date february registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture date december registrant chase manhattan bank trust company national association include form note indenture date december registrant jp morgan trust company national association include form note registration right agreement date december registrant goldman sach co amendment amend restate right agreement date october registrant mellon investor service llc form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee registrant incentive stock option plan relate agreement registrant supplemental stock option plan relate agreement registrant employee stock purchase plan amend march registrant stock option plan amend restate april amend january amend january form nonqualified stock option issue certain executive officer director vintage park research development net lease registrant vintage park associate date march premise locate b lakeside drive foster city california relate addendum exhibit amendment letter agreement date september registrant iocbrega exhibit certain confidential information omit amendment agreement date october registrant iocbrega relate license agreement exhibit certain confidential information omit amendment agreement date december registrant iocbrega loan agreement date october registrant mark l perry melanie p pea registrant nonemployee director stock option plan amend january amend january amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa date august certain confidential information omit development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september certain confidential information omit nexstar pharmaceutical incs incentive stock plan adopt february amend nexstar pharmaceutical inc director option plan adopt july vestar inc stock option plan lease date march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto date june amendment date january majestic realty co patrician associates inc registrant lease date march vestar inc majestic realty co patrician associates inc assignment royalty agreement date december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc date august amendment thereto date amendment agreement fujisawa usa inc vestar inc date april fujisawa usa inc vestar inc certain confidential information omit amendment agreement fujisawa usa inc registrant date march agreement fujisawa usa inc vestar inc date august lease date april vestar inc majestic realty co patrician associates inc amendment lease date april majestic realty co patrician associates inc vestar inc amend lease date april majestic realty co patrician associates inc vestar inc license distribution agreement date september sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc certain confidential information omit settlement agreement date august nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omit amendment date april sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc license distribution agreement date september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan licensing agreement date april gilead world market limited glaxo group limited employment agreement date july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch date august license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd date march license agreement triangle pharmaceuticals inc emory university coviracil ftc date april exclusive license agreement triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date amendment license agreement triangle pharmaceuticals inc emory university date amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date july second amendment license agreement triangle pharmaceuticals inc emory university date july supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories date july settlement exclusive license agreement triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august second amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date august manufacture supply agreement gilead world markets ltd ppgsipsy sas enter january gilead sciences inc severance plan adopt effective january amendment license agreement triangle pharmaceuticals inc emory university date lease agreement date june th registrant gra associates limited llc premise locate university drive durham north carolina master clinical commercial supply agreement date january gilead world markets ltd gilead sciences inc patheon inc toll manufacturing agreement date august gilead world markets ltd gilead sciences inc altana pharma oranienburg gmbh licensing agreement date march amend december april gilead sciences inc eyetech pharmaceuticals inc amendment licensing agreement date eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement date december eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement date august eyetech pharmaceuticals inc gilead sciences inc amendment date license agreement date april glaxo group limited gilead world market limited amendment date january licensing agreement date april glaxo group limited gilead world market limited subsidiary registrant consent ernst young llp independent auditor power attorney reference signature section certification section certification section certification file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end december incorporate reference file exhibit nexstar pharmaceutical inc quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file march incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file march exhibit nexstar pharmaceutical inc registration statement form file incorporate reference file exhibit nexstar pharmaceutical inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceutical inc registration statement form amend incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc current report form k file september incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act b report form k october company file form k announce earning company quarter month end september october company file form k announce board director approve amendment company amend restate right agreement originally adopt november amend restate october november company file form k announce purport class action complaint file november united states district court northern district california company company chief executive officer chief financial officer executive vice president operation research development senior vice president manufacture research gilead sciences inc consolidated financial statement year end december content report ernst young llp independent auditor audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report ernst young llp independent auditor board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list item annual report financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audit conduct audits accordance auditing standard generally accept united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity accounting principle generally accept united states opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective january company change method accounting derivative instrument hedging activity ernst young llp palo alto california january gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security account receivable net allowance doubtful account december december note receivable triangle pharmaceutical inc inventory defer tax asset prepay expense total current asset property plant equipment net noncurrent defer tax asset noncurrent asset liability stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit accrue liability defer revenue longterm obligation year total current liability longterm defer revenue longterm obligation year convertible senior debt convertible subordinated debt commitment contingency stockholder equity prefer stock par value share issuable series share authorize outstanding common stock par value share share authorize share issue outstanding december december respectively additional paidin capital accumulate comprehensive income defer compensation accumulate deficit total stockholder equity accompany note gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative inprocess research development asset impairment total cost expense income loss operation gain sale oncology asset gain sale unconsolidated affiliate loss sale marketable security interest income net interest expense income loss provision benefit income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle provision benefit income taxis equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute accompany note gilead sciences inc consolidated statement stockholder equity thousand accumulate additional comprehensive total common stock paidin income defer accumulate stockholder balance dece mber h u not c p l lo com pen ion e f c e q u net income unrealize gain available forsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan amortization defer compensation compensatory stock transaction balance december net income unrealize loss available forsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan compensatory stock transaction balance december net loss unrealize loss available forsale security net foreign currency translation adjustment unrealize loss cash flow hedge net comprehensive loss conversion convertible subordinate debt acquisition triangle pharmaceuticals inc employee stock purchase plan option exercise net tax benefit employee stock plan amortization defer compensation compensatory stock transaction balance december accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development asset impairment net effect change accounting principle gain sale oncology asset gain sale unconsolidated affiliate loss sale marketable security equity loss unconsolidated affiliate net movement provision doubtful account defer tax asset tax benefit employee stock plan noncash transaction change operate asset liability account receivable inventory prepaid expense asset account payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale maturity marketable security acquisition triangle net asset net cash acquire acquisition real estate capital expenditure issuance note triangle proceed sale oncology asset proceed sale unconsolidated affiliate net cash provide investing activity financing activity proceed issuance common stock repayment longterm debt proceed issuance convertible senior note net issuance cost net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity osi common stock receive sale oncology asset common stock issue conversion debt reclassification defer debt issuance cost additional paidin capital conversion subordinate debt accompany note gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead incorporate delaware june biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company revenue approve product marketing operation country focus research clinical program antiinfective currently market viread tenofovir disoproxil fumarate emtriva emtricitabine treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent vistide cidofovir injection treatment cmv retinitis roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquisition net asset triangle pharmaceuticals inc complete january internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop clinical stage product treat hiv infection chronic hepatitis b accompany consolidated financial statement include account gilead wholly majorityowne subsidiary significant intercompany transaction eliminate certain prior period amount reclassify consistent current year presentation stock split february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present reflect splitschange accounting principle gilead adopt statement financial accounting standard sfas nos collectively refer sfas accounting derivative instrument hedge activitiesin quarter change account change accounting principle note critical accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis management evaluate estimate include related revenue recognition bad debt inventory income taxis accrue clinical preclinical expense contingency base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure provide customer general right product return accept return product expire year expiration product deem damage defective receive customer recognition revenue product sale provision expect return expire product government reimbursement customer incentive cash discount prompt payment estimate government reimbursement cash discount base contractual term expectation utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern purchase party datum assist company monitor channel inventory level subsequent prescription contract revenue research development record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur performance obligation complete accordance specific term gilead obligation contract revenue recognize manufacturing obligation fulfil ratably development period period manufacturing obligation appropriate revenue associate substantive performance milestone recognize base achievement milestone completion performance requirement define respective agreement revenue research development cost reimbursement contract recognize related cost incur advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale vistide tamiflu recognize receive quarter follow quarter correspond sale occur shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component rd expense consist personnel cost include salary benefit clinical study perform contract research organization cro material supply overhead allocation consist administrative facility relate cost research development activity separate main category research clinical development gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis charge clinical preclinical study cost expense incur consistent sfas accounting research development cost cost significant component rd expense clinical preclinical study perform party cro accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort actually incur cro initially estimate work perform contract occur ratably service period expect milestone event total contract completion date expect completion date estimate base term contract pastexperience similar contract monitor level performance contract include extent patient enrollment activity communication cro adjust estimate require quarterly basis expense reflect actual effort incur cro material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate contract include additional termination payment payable gilead terminate contract additional termination payment record expense contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbase compensation accordance provision sfas accounting stockbase compensation amend sfas accounting stockbase compensationtransition disclosure sfas elect continue follow accounting principle board opinion apb accounting stock issue employee interpretation fin account certain transaction involve stock compensationan interpretation apb opinion accounting employee stock option plan apb exercise price gilead employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize elect follow intrinsic value method prescribe apb continue evaluate approach accounting stock option light ongoing industry regulatory development gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue table present combine net income loss basic diluted net income loss common share compensation cost gilead nexstar pharmaceuticals inc nexstar triangle stock option plan employee stock purchase plan espp determine base estimate fair value award plan grant purchase date accordance sfa thousand share amount year end december net income lossa report add stockbased employee compensation expense include report net income loss net relate tax effect deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss net income loss share basica report basicpro forma diluteda report dilutedpro forma effect net income loss basic diluted net income loss common share present likely representative effect net income loss net income loss share pursuant sfas future year subsequent year include additional grant year vest gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue fair value award grant stock option plan espp estimate grant purchase date blackschole option pricing model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility employee stock option characteristic significantly different trade option change subjective input assumption materially affect fair value estimate management opinion exist model necessarily provide reliable single measure fair value employee stock option multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield end quarter fair value stock award grant determined utilize volatility rate fourth quarter change volatility assumption arrive fair value stock award recent twoyear time period purpose calculate expect volatility consider factor stage development length time public company drug approval past year enable achieve positive cash flow operation believe volatility rate well reflects expect volatility stock go forward volatility table represents weight average volatility quarter fourth quarter weight average estimate fair value espp share purchase share computation basic diluted net loss common share compute base weighted average number common share outstanding period potential common share convertible note million share outstanding stock option warrant million share exclude computation dilute net loss share effect antidilutive basic net income common share compute base weighted average number common share outstanding period dilute net income common share include effect approximately million stock option include effect million convertible note convert approximately million share gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue million convertible note convert approximately million share effect assume conversion antidilutive diluted net income common share include effect approximately million stock option warrant include effect million convertible note convert approximately million share effect assume conversion antidilutive cash cash equivalent consider highly liquid investment insignificant interest rate risk remain maturity month purchase date cash equivalent enter overnight repurchase agreement purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repurchase agreement repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead eligible investment investment policy include commercial paper money market fund bank obligation marketable security determine appropriate classification marketable security consist solely debt security time purchase reevaluate designation balance sheet date marketable security classify availableforsale carry estimate fair value report cash equivalent marketable security december cash cash equivalent include million security designate availableforsale million december unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year concentration credit risk subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale significant trade account receivable arise sale ambisome viread primarily gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continuedsale european subsidiary export sale distributor europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past base contractual term receivable december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe past account receivable reflect consolidated balance sheet include customer country collectible perform credit evaluation customer financial condition generally require collateral material utilize operation facility example depend single supplier high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol manufacture ambisome supply supplier interrupt reason unable ship viread ambisome hepsera emtriva vistide supply product development clinical trial inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item item observe alternate use inventory record writedown net realizable value period unit identify impair historically inventory writedown insignificant consistent management expectation property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method land depreciate estimate useful life follow year description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement life relate lease gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term item useful life capitalize interest construction progress include property plant equipment intangible asset intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable inplace lease intangible asset amortize remain period relate lease term discuss note impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment food drug administration regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset impairment loss measure excess carrying value asset fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time gilead science incnote consolidated financial statement continue december organization summary significant accounting policy continue foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income accumulate separate component stockholder equity net foreign exchange transaction gain loss report sell general administrative expense consolidate statement operation realize gain loss million million million hedge certain foreign currency exposure related outstanding trade account receivable firmly commit purchase transaction forecast product sale foreign exchange forward contract general contract expose market risk gain loss contract offset gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction write option presently hedge net investment foreign subsidiary accounting hedge account receivable record change fair value sell general administrative expense derivative instrument designate hedge sfas selectively hedge anticipate currency exposure purchase forward contract hedge firmly commit purchase transaction anticipate product sale year designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income recognize earning forecast transaction occur december december net unrealized loss open foreign exchange forward contract million million respectively loss revenue hedge reduce product sale million million notional amount forward exchange contract outstanding million december million december contract maturity year note discussion derivative financial instrument adoption sfas fair value financial instrument company financial instrument consist principally cash cash equivalent marketable security account receivable certain noncurrent asset forward foreign exchange contract account payable longterm obligation convertible note cash cash equivalent marketable security forward foreign exchange contract hedge account receivable report respective fair value balance sheet forward foreign exchange contract hedge firmly commit purchase sale record fair value net relate deferred gain loss result report net balance zero fair value convertible senior note december gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue million fair value december million carrying value end period million fair value convertible subordinated note december million carrying value million gilead call convertible subordinate note redemption november convert gilead common stock december fair value december december convertible note determine obtain quote market maker note believe remain financial instrument report consolidated balance sheet amount approximate current fair value recent accounting pronouncement january fasb issue fasb interpretation fin consolidation variable interest entity interpretation arb fin require certain variable interest entity consolidate primary beneficiary entity equity investor entity characteristic control financial interest sufficient equity risk entity finance activity additional subordinate financial support party fin effective immediately new variable interest entity create acquire january create acquire new variable interest entity january variable interest entity create acquire prior february provision fin amend apply end interim annual period end march adoption fin material impact consolidate financial statement derivative financial instrument january gilead adopt sfas standard require gilead recognize derivative asset liability measure fair value enter foreign currency forward contract hedge change fair value monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning company enter foreign currency forward contract generally maturitie month hedge future cash flow related purchase transaction forecast product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify accordance sfas hedge relate anticipate foreign currency purchase raw material forecast product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness quarterly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract change forward value underlie hedged item effective component hedge record accumulate comprehensive income substantially value report accumulate comprehensive income december reclassify toearning month residual change fair value instrument ineffectiveness gilead sciences inc note consolidated financial statement continue december derivative financial instrument continue recognize immediately sell general administrative expense ineffectiveness significant result enter collaboration prior year gilead hold warrant purchase stock nonpublic company complete initial public offering january note warrant net exercise feature sfas classify derivative instrument adoption gilead record fair value warrant million offset adjustment cumulative change accounting principle million loss hedge contract recognize consolidated income statement million decrease fair value derivative recognize accumulate comprehensive income december fair value derivative include accumulate comprehensive income material acquisition triangle pharmaceuticals inc january complete acquisition net asset triangle expand antiviral pipeline triangle development stage company particular focus potential therapy hiv include aids hepatitis b virus hbv triangle portfolio consist drug candidate clinical trial include emtriva emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july food drug administration fda approve marketing emtriva treatment hiv october european commission grant marketing authorisation emtriva member states european union triangle acquisition account acquisition asset business combination accordance criterion outline emerge issue task force triangle development stage company commence plan principal operation lack necessary element business complete product ability access customer result operation triangle january include consolidated financial statement primarily consist research development expense less extent sell general administrative expense december arrangement contemplate propose acquisition triangle gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion acquisition january loan eliminate consolidated financial statement aggregate purchase price million include cash pay million outstanding stock fair value stock option assume million estimate direct transaction cost million employee relate cost million purchase establish workforce reduction plan assume obligation change control agreement acquisition date approximately million employee termination cost change control obligation record liability pay gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue period approximately year december approximately million remain liability follow table summarize purchase price allocation january thousand net tangible asset assemble workforce defer compensation inprocess research development million net tangible asset includes assume liability million million value assign assemble workforce amortize year estimate useful life asset defer compensation represent intrinsic value unvested stock option assume transaction amortize remain vest period option extend january reversal defer tax asset valuation allowance fourth quarter remain million assemble workforce asset eliminate note gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue approximately million purchase price allocate inprocess research development represent fair value triangle incomplete research development program reach technological feasibility alternative future use acquisition date summary program acquisition date update subsequent development follow value program description status development million emtricitabine nucleoside analogue phase study complete hivsingle show marketing approval receive agent inhibitor hiv replication fda july european union patient approval receive european commission october emtricitabine potential coformulation acquisition date work tenofovir df tenofovir emtricitabine commence potential co fix dose formulation extent work combination emtricitabine single agent hiv therapy progressing successfully complete coformulate tenofovir emtricitabine single pill complete stability study bioequivalence study require approval amdoxovir hiv purine dioxolane phase trial acquisition date nucleoside offer effective january announce advantage intent terminate licensing market nucleosides agreement emory university activity university georgia research drug resistant viruses foundation inc development exhibit patient hiv discontinue infection clevudine hbv pyrimidine nucleoside phase trial acquisition date analogue effective august licensing show inhibitor agreement bukwang pharm ind co hbv replication patient ltd terminate development chronically infect discontinued hbv emtricitabine inhibitor hbv phase trial ongoing hbv replication patient chronically infect hbv gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue remain effort completion triangle research development project primarily consist clinical trial cost length success extremely difficult predict numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain emtricitabine treatment chronic hepatitis b purchase triangle approve european union marketing approval significant limitation use terminate right respect potential product acquire acquisition triangle approval fixeddose combination product contain tenofovir df emtricitabine future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product development successfully commercialize emtriva example product similaritie exist product result difficult successfully penetrate market achieve significant revenue addition emtricitabine treatment chronic hepatitis b face significant uncertainty associate pricing efficacy cost produce successfully resolve result strategic decision discontinue development product clevudine amdoxovir believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact value acquire inprocess research development determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete thedevelopment approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market acquisition real estate september complete purchase foster city campus approximately million cash purchase include building total square foot office laboratory space lakeside drive foster city california accordance sfas business combination sfas goodwill intangible asset purchase price allocate land building exist inplace lease base estimate relative fair value land building record million gilead sciences inc note consolidated financial statement continue december acquisition real estate continue million respectively fair value building depreciate remain economic life estimate year market approach value exist lease acquire record intangible asset approximately million amortize straightline basis net rental income approximately year remain term lease net rental income generate lease amortization intangible asset include interest income net approximately million year end december accumulate amortization intangible asset million december asset impairment record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment classify hold use noncash charge drive decision terminate liposomal research development activity san dimas discontinue daunoxome product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related undiscounted cash flow write carry value longlive asset fair value accordance sfas accounting impairment disposal longlive asset fair value derive expected cash flow approach sale oncology asset december gilead complete sale oncology asset pipeline clinical candidate oncology relate intellectual property boulder colorado operation include clinical research drug development operation infrastructure facility osi clinical development candidate sell osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor consideration gilead receive million cash share osi common stock value approximately million december number share issue gilead determine divide million average closing sale price osi common stock day precede december entitle additional payment osi million cash combination cash osi common stock osi reach certain development milestone nx advanced oncology product candidate sell osi milestone payment receive osi recognize contract revenue receipt base december net book value oncology asset sell million transaction cost million million relate acceleration approximately option purchase gilead common stock realize pretax gain million fourth quarter carry value transfer asset relate primarily certain property equipment osi assume gilead oncologyrelate clinical preclinical obligation lease obligation relate manufacturing agreement produce osi liposomal formulation nx gs l liposomal product sell osi manufacturing facility san dimas gilead sciences inc note consolidated financial statement continue december sale marketable security july gilead sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million reflect consolidated result operation year end december availableforsale security follow summary availableforsale security estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross unrealize unrealized estimate cost gain loss fair value december treasury security obligation government agency corporate debt security assetbacke security debt security total december treasury security obligation government agency corporate debt security assetbacke security debt security total debt security consist primarily money market fund maintain marketable security nominal value record noncurrent asset december december security net unrealize loss approximately million million respectively follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale gilead sciences inc note consolidated financial statement continue december availableforsale security continue december million portfolio marketable security exclude million assetbacked security contractual maturity year million portfolio contractual maturity great year year estimate maturity assetbacked security exceed year balance sheet detail thousand december inventory raw material work process finish good total property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress accumulate depreciation amortization subtotal land total accrue compensation employee benefit accrue bonus accrue compensation employee benefit total accrue liability accrue medicaid rebate fair value forward currency contract income taxis payable accrue sale marketing expense liability total gilead sciences inc note consolidated financial statement continue december collaborative arrangement contracts chiron corporation august enter nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutic select hepatitis c virus hcv drug target agreement gilead receive nonexclusive right use chiron hcv technology develop commercialize product treatment hcv term agreement pay chiron upfront license fee record research development expense future alternative use technology agree additional payment chiron certain clinical regulatory milestone meet royalty payment event product develop licensed technology japan tobacco inc july gilead enter licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize product hiv portfolio japan agreement include viread emtriva future coformulation product term agreement receive fee entitle receive additional cash payment achievement certain milestone japan tobacco pay royalty net sale product japan upfront fee record defer revenue amortize contract revenue period remain obligation agreement approximately year emory university april triangle obtain january acquire acquisition triangle exclusive worldwide license emory universitys right purify form emtricitabine use hiv hepatitis b field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology year registration grant antihepatitis b product incorporate emtricitabine technology certain major market country hiv hepatitis b indication respectively triangle begin pay license maintenance fee development milestone achieve license agreement emory terminate late patent expiration expiration obligation pay royalty addition right terminate agreement entirety respect indication hiv hbv country prior expiration time day notice glaxosmithkline april gilead gsk enter licensing agreement provide gsk right commercialize hepsera antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera u canada eastern western europe australia new zealand gsk receive exclusive right develop hepsera solely gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue treatment chronic hepatitis b territory significant include china korea japan taiwan addition gsk pay licensing fee million payment additional obligation pay million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera september million receive canadian approval hepsera august gsk pay royalty net sale hepsera gsk territory gsk responsibility development commercialization hepsera gsk territorie million upfront fee million approval fee record defer revenue total million million recognize contract revenue respectively million balance defer revenue december amortize contract revenue period remain obligation agreement approximately year december gilead enter agreement glaxo wellcome gsk give gilead right gs l novel antitumor compound gilead develop gs l liposome evaluate preclinical study agreement gilead exclusive worldwide right develop commercialize gs l indication malaria gilead pay gsk upfront fee include rd expense december compound assign osi sale oncology asset gilead enter threepart collaboration gsk gsk receive nonexclusive right use gilead proprietary selex process target validation b gilead receive exclusive right subject gsk right elect participate activity develop commercialize nx liposomal formulation gsk proprietary topoisomerase inhibitor lurtotecan c gsk acquire share gilead common stock million private offering december collaboration license agreement modify revise term agreement gsk waive right participate development commercialization nx right receive royalty give gilead exclusive right compound december compound assign osi sale oncology asset cubist pharmaceutical september gilead cubist pharmaceutical jointly announce termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin agreement execute january grant gilead exclusive commercialization right product european country follow regulatory approval term termination agreement gilead owe future payment cubist cubist reacquire european right product termination million record research development expense represent remain unamortized asset relate preclinical oral formulation daptomycin gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue archemix october enter agreement archemix corporation relate selex technology agreement archemix obtain exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement license equity holdings inc ulehi pay receipt ulehi recognize million million revenue respectively receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant time transfer remainder warrant ulehi additional payment archemix agreement eyetech march enter agreement eyetech pharmaceuticals inc relate proprietary aptamer eye know macugen currently phase clinical trial macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product eyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue agreement remainder license fee recognize revenue entitle additional cash payment eyetech million eyetech reach certain macugen development milestone additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor note description account treatment warrant fujisawa right market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa term fujisawa agreement amend fujisawa gilead copromote ambisome fujisawa sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty fujisawa connection sale significant asian market include japan connection sales fujisawa purchase ambisome gilead cost sale canada fujisawa purchase ambisome cost plus specify percentage fujisawa collect payment sale ambisome canada receive fujisawa gross profit sale ambisome gross profit include deduction cost good sell give current effective royalty rate approximately fujisawa net sale ambisome gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue connection agreement fujisawa record royalty revenue million million million sumitomo september gilead sumitomo enter agreement pursuant sumitomo agree develop market ambisome japan term agreement sumitomo pay initial million licensing fee withholding taxis million october million milestone payment withholding taxis million march sumitomo require additional payment certain clinical commercial milestone meet pay royalty japanese ambisome sale agreement gilead obligate provide certain quantity ambisome sumitomo charge ambisome approve marketing japan roche september gilead enter collaboration agreement roche develop commercialize therapy treat prevent viral influenza roche agreement roche agreement roche receive exclusive worldwide right gilead proprietary influenza neuraminidase inhibitor prior roche license fee developmental milestone payment total million gilead recognize million contract revenue milestone payment roche relate tamiflu milestone achieve year milestone include file regulatory approval japan treatment influenza japanese approval application file regulatory approval prevention influenza receipt approval recognize million milestone payment filing application market tamiflu prophylaxis european union recognize million milestone payment european approval tamiflu treatment prophylaxis december gilead entitle additional cash payment roche million roche achieve additional developmental regulatory milestone addition roche require pay gilead royalty net product sale gilead begin receive royalty roche sale tamiflu quarter record total million tamiflu royalty million royalty million royalty recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur pfizerin august gilead pfizer pharmacia corporation enter license supply agreement pfizer agreement market vistide country outside term pfizer agreement pfizer pay gilead initial license fee million subsequent cumulative effect change accounting principle record effective quarter gilead recognize initial license fee straightline basis supply arrangement period sixteen year agreement date net impact change accounting principle pfizer agreement increase net loss million gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue cumulative effect change accounting principle relate initial license fee pfizer million charge result operation additional contract revenue million recognize subsequent accounting change remain million relate deferred revenue expect recognize straightline basis contract revenue remain supply period term pfizer agreement relate agreement cover expand access program vistide outside gilead responsible maintain cidofovir patent portfolio supply pfizer bulk cidofovir manufacture finish vistide product gilead entitle receive royalty base pfizer sale vistide gilead receive portion royalty ship bulk drug substance vistide pfizer remainder pfizer sale vistide party royalty gilead receive product sell party record defer revenue thirdparty sale occur december record balance sheet approximately million defer revenue million december recognize royalty revenue sale vistide outside united states pharmacia million million million iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide hepsera viread exclude tamiflu gilead currently make quarterly payment iocbrega base percentage vistide hepsera viread sale december agreement iocbrega amend provide reduce royalty rate future sale hepsera viread return payment gilead million signing agreement payment record longterm prepay royalty classified noncurrent asset balance sheet december recognize royalty expense expect commercial life viread hepsera amortization million payment begin product launch date viread hepsera total million december southern research institute december gilead enter agreement southern research institute give gilead worldwide right develop commercialize gs antitumor compound gilead evaluate preclinical study term agreement gilead pay southern research institute upfront fee include research development expense december compound assign osi sale oncology asset gilead sciences inc note consolidated financial statement continue december investment sale unconsolidated affiliate july establish proligo llc delaware limited liability company proligo wholly own subsidiary transfer asset nexstar technology product division proligo august sell interest interest proligo party payment interest receive million cash interest perseptive biosystem gmbh company hamburg germany specialize manufacture nucleoside phosphoramidite monomer prior february additional cash investment proligo total million maintain ownership interest proligo account investment proligo equity method accounting gilead sell interest proligo degussa corporation million cash proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate prior date sale gilead record million equity loss proligo longterm obligation longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range fix rate debt monthly installment secure equipment interest rate range total longterm obligation current portion longterm obligation year future minimum lease payment capital lease obligation follow thousand year end december represent interest total term agreement require comply certain financial operating covenant december compliance covenant gilead sciences inc note consolidated financial statement continue december convertible note december gilead issue million convertible senior note december private offer goldman sachs co resold note qualified institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option gilead time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note december gilead issue million convertible subordinated note december private offering jp morgan co lehman brothers morgan stanley dean witter resold note private institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option gilead time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance thenote record noncurrent asset amortize interest expense straightline basis contractual term note november gilead call convertible subordinate note redemption convert share common stock december conversion million remain balance relate debt issuance cost reclassify additional pay capital commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease san dimas california durham north carolina expire date san dimas lease contain fiveyear renewal option durham lease sevenyear renewal option operate lease sale marketing administrative facility europe australia term equipment lease include corporate airplane initial term year annual renewal option year lease expense net sublease income operating lease total approximately million million million gilead sciences inc note consolidated financial statement continue december commitment contingency continue aggregate noncancelable future minimum rental payment operating lease net aggregate future minimum rental receive noncancelable sublease follow thousand operating lease net year end december noncancelable sublease future minimum rental receipt noncancelable sublease million million million legal proceeding reach settlement elan corporation plc elan successor company liposome company company agree dismiss legal proceeding involve ambisome gilead liposomal formulation amphotericin b term initial settlement agreement initial payment elan million agree additional royalty payment base ambisome sale record million accounting charge accrue litigation settlement expense represent estimate net present value future minimum payment require june elan gilead enter agreement terminate remain ambisome payment obligation initial settlement agreement exchange payment elan million excess million settlement remain accrue litigation settlement expense balance million amortize remain life patent approximately year september gilead enter settlement agreement release university license equity holdings inc ulehi archemix corporation concern right identify aptamer selex technology license ulehi gilead settlement agreement release resolve dispute party arise gilead assignment right identify certain aptamer archemix september county westchester new york westchester serve gilead complaint allege gilead large number pharmaceutical manufacturer defendant report price product overstate average wholesale price awp allegedly inflate reimbursement rate medicaid program cause westchester pay artificially inflate price cover drug include case gilead viread addition westchester argue defendant include gilead accurately report good price medicaid program complaint assert vary claim federal rico statutes state law corollary state law claim deceptive trade practice common law fraud gilead intends vigorously defend gilead sciences inc note consolidated financial statement continue december commitment contingency continue allegation complaint seek undetermined damage relief include declaratory injunctive relief defendant lawsuit name numerous lawsuit comparable awp allegation knowledge gilead name lawsuit gilead name serve lawsuit comparable awp allegation adverse result result material damage purport class action complaint file november united states district court northern district california gilead company chief executive officer chief financial officer executive vice president operation research development senior vice president manufacture research complaint allege defendant violate federal security law specifically section b securities exchange act rule b securities exchange commission make certain allege false misleading statement plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december believe meritorious defense allegation contain complaint intend defend case vigorously trial date schedule february court issue order appoint lead plaintiff action lead plaintiff march file consolidate complaint december purport shareholder derivative lawsuit file individual shareholder behalf gilead director certain executive officer superior court state california county san mateo allege thing defendant violate california corporations code breach fiduciary duty owe gilead gilead name nominal defendant plaintiff seek unspecified damage behalf gilead connection allege insider trading period july october defendant allege breach fiduciary duty abuse control waste mismanagement case consolidate single action january plaintiff file consolidated complaint february trial date schedule intend appropriate action defend interest connection litigation party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position stockholder equity prefer stock gilead share authorize preferred stock issuable series board directors board authorize determine designation power preference right series reserve share prefer stock potential issuance preferred share purchase right plan prefer stock outstanding december december gilead sciences inc note consolidated financial statement continue december stockholder equity continue employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensation purchase price share equal low percent market value date offer date purchase total million share ofcommon stock reserve issuance espp december million share total share reserve issue espp million share december stock option plan december gilead adopt incentive stock option plan supplemental stock option plan issuance common stock employee consultant scientific advisor april board approve grant certain additional nonqualified stock option term condition substantially similar grant supplemental stock option plan option issue plan describe exercise price fair value underlie stock date grant option vest year pursuant formula determine board expire year share available grant future option plan november gilead adopt stock option plan plan issuance common stock employee consultant option issue plan shall discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year plan amend restate april extend term plan stockholder approve amendment plan increase total number authorize share plan december share available grant future option plan november gilead adopt nonemployee director stock option plan director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option grant january vest year date grant quarterly percent installment initial option grant january new director vest year date grant equal annual installment annual grant exist director vest month option expire year stockholder approve amendment director plan increase total number authorize share plan december share available grant future option director plan stock plan assume gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plan option pursuant nexstar plan issue outstanding july gilead sciences inc note consolidated financial statement continue december stockholder equity continue convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan nexstar plan allow certain option holder execute cashless exercise option cashless exercise transaction option holder specify share exercise gilead issue specify number share number require cover exercise price base fair value stock exercise date option holder perform cashless exercise result option award consider variable recognize nominal compensation expense million july option outstanding category stock plan assume gilead acquisition net asset triangle include stock option plan separate plan chief executive officer triangle collectively triangle plan option pursuant plan issue outstanding january convert option purchase approximately million share gilead common stock result acquisition remain subject original term condition share available grant future option triangle plan follow table summarize activity gilead nexstar triangle stock option plan year period end december option grant present table exercise price fair value underlie stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weight average fair value option grant gilead sciences inc note consolidated financial statement continue december stockholder equity continue follow summary gilead option outstanding option exercisable december option thousand option outstanding option exercisable weighted average weight remain average weighted option contractual exercise option average range exercise price outstanding life year price exercisable exercise price total company reserve aggregate million share common stock future issuance equity compensation plan december include million issuable espp million issuable stock option plan approximately million share reserve issuance senior convertible note prefer share purchase right plan november adopt preferred share purchase right plan right plan plan provide distribution prefer stock purchase right dividend share gilead common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase gilead common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade gilead common stock october october board director approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan adjust stock split extension term right plan october acceleration stock option december complete sale oncology asset osi transaction accelerate approximately option purchase gilead common stock value million note discussion gilead sciences inc note consolidated financial statement continue december comprehensive income loss follow reclassification adjustment require avoid doublecounte net realize gain loss sale security previously include comprehensive income loss prior sale security thousand year end december net gain loss sale security comprehensive income net unrealize gain loss arise year reclassification adjustment net unrealized gain loss report comprehensive income loss balance accumulate comprehensive income report balance sheet consist follow component thousand december net unrealized gain loss availableforsale security net unrealize gain loss cash flow hedge net foreign currency translation gain loss accumulate comprehensive income disclosure segment enterprise related information sfas disclosure segment enterprise related information sfas establishe standard way public business enterprise report information operate segment annual financial statement require enterprise report select information operating segment interim financial report sfas establish standard relate disclosure product service geographic area major customer company operate business segment primarily focus development commercialization human therapeutic infectious disease product aggregate segment majority product viread ambisome account sale similar economic characteristic similarity include nature product production process type customer distribution method regulatory environment company derive revenue primarily product sale viread ambisome royalty contract revenue royalty revenue relatesprimarily sale ambisome fujisawa sale tamiflu roche contract revenue relate license selex process patent estate archemix milestone payment roche relate development tamiflu license milestone payment gsk related development hepsera license fee eyetech right aptamer eye currently know macugen gilead sciences inc note consolidated financial statement continue december disclosure segment enterprise relate information continue product sale consist follow thousands year end december viread ambisome follow table summarize revenue external customer collaborative partner geographic region revenue attribute country base location customer collaborative partner thousand year end december united states united kingdom france spain germany italy switzerland european country country consolidate total revenue december net book value property plant equipment million approximately asset locate december net book value property plant equipment million approximately asset locate product sale distributor account approximately total revenue product sale distributor account approximately total revenue product sale distributor exceed total revenue total revenues fujisawa include product sale royalty approximately total revenue gilead sciences inc note consolidated financial statement continue december income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer foreign pretax loss million million million company foreign subsidiary generate operating loss reflect cost build commercial infrastructure europe foreign subsidiary investment company research development effortsthe difference provision taxis income compute apply federal statutory income tax rate income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle explain thousands year end december income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate previously unbenefitte net operating loss state taxis net federal benefit federal alternative minimum taxis reversal valuation allowance purchase inprocess research development foreign loss different rate foreign earning different rate gilead sciences inc note consolidated financial statement continue december income taxis continue tax benefit associate stock option exercise employee stock purchase plan result cumulative tax benefit million year end december benefit credit additional paidin capital realize deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability december follow thousand december net operating loss carryforward research credit capitalize research development expense reserve accrual currently deductible net total defer tax asset valuation allowance net defer tax asset recognize valuation allowance decrease million year end december increase million year end december december base level historical taxable income projection future taxable income period defer tax asset deductible determine likely certain defer tax asset realize release related valuation allowance reversal valuation allowance result realization income tax benefit approximately million defer tax asset attributable net operating loss carryforward include tax benefit million relate exercise employee stock option benefit record directly additional pay capital reversal valuation allowance result reduction remain assemble workforce asset million establish acquisition triangle december remain valuation allowance million net defer tax asset conclude base standard set forth sfas accounting income taxis likely realize benefit relate deferred tax asset assess need valuation allowance quarter end base available evidence approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital realize december federal net operating loss carryforward approximately million state net operating loss carryforward approximately million federal net operating loss carryforward expire date begin utilize state net operating loss carryforward expire date gilead sciences inc note consolidated financial statement continue december income taxis continue utilize addition federal state tax credit carryforward approximately million million respectively expire year utilization net operating loss credit subject annual limitation ownership change limitation provide internal revenue codeand similar state provision annual limitation result expiration net operating loss credit utilization retirement saving plan december gilead maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code prior january gilead maintain separate retirement saving plan plan primarily cover nexstar employee nexstar plan plan primarily cover gilead remain eligible employee gilead plan december approximately million represent share gilead common stock hold nexstar plan trust plan participant effective january nexstar plan terminate combined gilead plan share gilead common stock hold nexstar plan subsequently liquidate proceed deposit investment option available gilead plan gilead plan employee contribute eligible annual compensation effective january gilead begin make match contribution gilead plan contribute employee contribution annual maximum match total matching contribution gilead plan million million million quarterly result unaudite follow table thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income loss net income loss common sharebasic net income loss common sharedilute gilead sciences inc note consolidated financial statement continue december quarterly result unaudite continued st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income loss net income loss common sharebasic net income loss common sharedilute quarter gilead complete acquisition net asset triangle record charge million inprocess research development quarter gilead reimburse million research development expense result settlement contractual dispute vendor fourth quarter gilead record noncash impairment charge certain longlive asset million million related asset writedown addition record income tax benefit million relate reduction valuation allowance certain net defer tax asset quarter gilead realize million nonoperate loss sale remain share osi pharmaceuticals inc gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge charge end period expense deduction period year end december allowance doubtful account allowance sale return valuation allowance defer tax asset year end december allowance doubtful account allowance sale return valuation allowance defer tax asset year end december allowance doubtful account allowance sale return valuation allowance defer tax asset charge current tax expense additional pay capital charge defer tax benefit charge current tax expense